Kistarcsa

• A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil … Not authorised
  2022-501361-44-00 5 Adult patients of either gender with active moderate to severe rheumat
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• A study to test if tenecteplase helps people to recover from an acute stroke when given more than 4.5 hours after the person was last seen w … Recruiting
  2025-522542-40-00 5 2026-06-19 Acute Ischemic Stroke
• A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Li … Recruiting
  2025-523847-36-00 3 2026-05-19 Participants with Mild, Moderate, or Severe Hepatic Impairment and Par
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody Recruiting
  2025-521416-19-00 4 2026-03-12 Recurrence of Clostridioides difficile Infection
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Pharmacokinetics of NTRX-07 in fed and fasted participants Recruiting
  2025-523695-23-00 3 2025-12-11 Not applicable (trial is a pharmacokinetic study in healthy volunteers
• A Phase 2b Study of IMVT-1402 Treatment in CIDP Recruiting
  2024-517614-14-00 4 2025-11-28 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A Study of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment Recruiting
  2025-521947-19-00 3 2025-11-19 Healthy, Hepatic Insufficiency
• Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting
  2024-515979-35-00 5 2025-11-13 Generalized Myasthenia Gravis
• International study to compare the efficacy and safety of chondroitin sulfate 800 mg tablets of two different origins (bovine versus marine) … Recruiting
  2024-516337-12-00 5 2025-08-07 Knee osteoarthritis with moderate to severe pain
• A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien … Recruiting
  2024-519059-28-00 5 2025-07-17 Chronic Heart Failure
• A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Late … Recruiting
  2023-507195-43-00 3 2024-07-01 Amyotrophic Lateral Sclerosis (ALS)
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici … Ended recruitment
  2025-521127-73-00 5 2025-09-12 Relapsing forms of Multiple Sclerosis
• A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liv … Ended recruitment
  2024-520315-40-00 3 2025-07-22 Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairme
• A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary ef … Ended recruitment
  2024-515907-20-00 9 2025-05-23 Primary biliary cholangitis (PBC)
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenanc … Ended recruitment
  2023-509320-17-00 6 2023-03-28 non-radiographic axial spondyloarthritis
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter

Showing 1–24 of 62 trials